what is a glp 1 antagonist Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment GIPR antagonist antibodies conjugated to

Diabetes 58 , 975983 (2009)

The clinical evidence base for GLP-1 therapy keeps expanding into new indication categories cardiovascular risk reduction, potential Alzheimer's benefit, heart failure management, sleep apnea, and kidney disease protection are all active investigation areas

Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study

Future research should concentrate on discovering optimum microbiome biomarkers for therapy selection and creating microbiome-targeted adjuvant medicines

Peptides 2023;162:170955.ArticlePubMed 109

Treatment with tirzepatide did not increase the odds of hypoglycaemia but was associated with increased incidence of gastrointestinal adverse events, mainly nausea